Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)
Condition: Cutaneous Squamous Cell Carcinoma in Situ (CSCCis) Interventions: Drug: Cutaneous Cream application; Drug: Placebo Cutaneous Cream application Sponsor: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2017 Category: Research Source Type: clinical trials
Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo ® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.
Conditions: Bladder Cancer; Bladder Neoplasm; Bladder Tumors; Cancer of Bladder; Cancer of the Bladder; Malignant Tumor of Urinary Bladder; Neoplasms, Bladder; Urinary Bladder Cancer; Carcinoma in Situ of Bladder; Papillary Carcinoma of Bladder (Diagnosis); BCG-Unresponsive Bladder Cancer Intervention: Combination Product: Synergo® RITE + MMC Sponsor: Medical Enterprises Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2017 Category: Research Source Type: clinical trials
Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)
Condition: Cutaneous Squamous Cell Carcinoma in Situ (CSCCis) Interventions: Drug: Cutaneous Cream application; Drug: Placebo Cutaneous Cream application Sponsor: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2017 Category: Research Source Type: clinical trials
Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo ® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.
Conditions: Bladder Cancer; Bladder Neoplasm; Bladder Tumors; Cancer of Bladder; Cancer of the Bladder; Malignant Tumor of Urinary Bladder; Neoplasms, Bladder; Urinary Bladder Cancer; Carcinoma in Situ of Bladder; Papillary Carcinoma of Bladder (Diagnosis); BCG-Unresponsive Bladder Cancer Intervention: Combination Product: Synergo® RITE + MMC Sponsor: Medical Enterprises Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2017 Category: Research Source Type: clinical trials
Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)
Condition: Cutaneous Squamous Cell Carcinoma in Situ (CSCCis) Interventions: Drug: Cutaneous Cream application; Drug: Placebo Cutaneous Cream application Sponsor: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2017 Category: Research Source Type: clinical trials
Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo ® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.
Conditions: Bladder Cancer; Bladder Neoplasm; Bladder Tumors; Cancer of Bladder; Cancer of the Bladder; Malignant Tumor of Urinary Bladder; Neoplasms, Bladder; Urinary Bladder Cancer; Carcinoma in Situ of Bladder; Papillary Carcinoma of Bladder (Diagnosis); BCG-Unresponsive Bladder Cancer Intervention: Combination Product: Synergo® RITE + MMC Sponsor: Medical Enterprises Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2017 Category: Research Source Type: clinical trials
Novel Molecular Targets for Ductal Carcinoma In Situ (DCIS)
Condition: Breast Cancer Intervention: Other: Biomarkers Sponsors: Sentara Norfolk General Hospital; George Mason University; Dorothy G. Hoefer Foundation Recruiting - verified May 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 1, 2017 Category: Research Source Type: clinical trials
